With Immunomedics ADC deal, Everest bolsters cancer pipeline

Undeterred by a complete response letter issued by FDA in January for Immunomedics' sacituzumab govitecan, Everest obtained the therapy's rights in several Asian territories, making the antibody-drug conjugate Everest's most advanced oncology asset thus far.

Everest Medicines Ltd. (Boston, Mass.) did adjust its offer following the CRL, maintaining interest in a deal as other bidders were likely wavering, according to Everest President and CFO Ian Woo...